Search the Newsreel

Lyell Immunopharma VP Bulis sells $8,905 of common stock

Veronica Sanchez Bulis, VP at Lyell Immunopharma (NASDAQ:LYEL), sold 621 shares for $8,905 to cover tax obligations from vested restricted stock units. The company's stock has been volatile, down 53% YTD, but holds more cash than debt despite burning through cash quickly. Lyell also …

Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding

Lyell Immunopharma's President and CEO, Lynn Seely, automatically sold 390 shares of common stock on August 10, 2026. This transaction was conducted to cover tax withholding obligations associated with vested restricted stock units. The shares were sold at a weighted average price of $14.34 …

Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes

Veronica Sanchez Bulis, VP and Corporate Controller at Lyell Immunopharma (LYEL), automatically sold 621 shares of common stock on August 10, 2026, at a weighted average price of $14.34 per share. This sale was conducted to cover tax withholding obligations associated with the settlement …

Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL

Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates

Lyell Immunopharma (NASDAQ: LYEL) reported second-quarter earnings per share of $-1.920, exceeding analyst estimates by $0.22. However, the company's revenue of $4K fell short of the consensus estimate of $5.5K. Despite a 23.580% drop in its stock price over the last three months, Lyell …

Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS

Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance

Lyell Immunopharma reported a GAAP net loss of $44.8 million for Q2 2026 and held $228.0 million in cash, expecting this to last into Q3 2027. The company announced advancing clinical milestones for its ronde-cel and LYL273 programs, including ongoing trials and upcoming data …

Lyell Immunopharma: Q2 Earnings Snapshot

Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on Lyell Immunopharma (NASDAQ:LYEL) with a "buy" rating and a $36.00 price target, suggesting a significant upside. This comes amidst generally favorable analyst sentiment, with an average "Moderate Buy" rating and a $42.00 target price from other firms. Lyell Immunopharma, …

LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36

Stifel has initiated coverage on Lyell Immunopharma, Inc. (LYEL.O) with a buy rating, setting a target price of $36. This announcement comes from Reuters and reflects an analyst's opinion on the company's prospects. The article also includes a disclaimer stating that the content is …

Lyell Immunopharma (LYEL) Earnings Date and Reports 2026 $LYEL

Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy

Stifel initiated coverage on Lyell Immunopharma (NASDAQ:LYEL) with a buy rating and a price target of $36.00, citing the potential of its Rondecabtagene autoleucel (Ronde-cel) CAR T-cell therapy. The firm believes Ronde-cel could achieve clinical superiority and regulatory approvals by 2028 and 2030, projecting …

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $2.0243 per share and $5,000 in revenue. Despite a consensus "Moderate Buy" rating and a target price of $43.20, the …

Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk

Lyell Immunopharma Inc (LYEL) has a current risk assessment score of 2.20, ranking 230 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of -0.09 suggests it tends to underperform during market uptrends but experiences smaller declines during downtrends. …

Enterprise value to revenue forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL

LYEL|Lyell Immunopharma Inc|Price:13.000|Chg%:+0.040

TradingKey provides a comprehensive stock analysis for Lyell Immunopharma Inc (LYEL), highlighting its relatively healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a late-stage clinical entity developing CAR T-cell therapies, has high institutional ownership and …

Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL

This article provides the "Price to book forward" value for Lyell Immunopharma, Inc. (NASDAQ: LYEL). It is a brief financial data point from TradingView, part of a larger financial overview for the company. The content primarily focuses on the specific metric within the platform's …

Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com

This article reports on a Form 4 filing for Lyell Immunopharma Inc. dated July 27. It includes the stock symbol LYEL and its performance for the day. The article appears to be a brief financial news update from Investing.com.

Lyell Immunopharma Market Sentiment

This article provides an overview of Lyell Immunopharma's (LYEL) market sentiment, detailing key signals such as analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with a high average price target, while options flow indicates a bearish sentiment with …

Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc. (LYEL), transferred 44,000 shares of common stock to Wuxiong, Inc. This transfer served as a non-cash broker commission related to a development milestone under a license agreement dated November 6, 2025. Following …

Broker commission transfer of 38,500 shares in Lyell Immunopharma (LYEL)

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma (LYEL), transferred 38,500 shares of common stock to LifeSci Advisors, LLC as broker commission on July 27, 2026. This transfer was related to the first Development Milestone payment under a November 6, 2025 …

Lyell Immunopharma Inc (LYEL) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Lyell Immunopharma Inc (LYEL), covering operating, investing, and financing activities. It presents financial data for various quarters, highlighting net income, capital expenditures, and changes in working capital. The report also includes FAQs …

Lyell Immunopharma Inc (LYEL) Institutional Confidence

Lyell Immunopharma Inc (LYEL) has an institutional shareholding score of 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 14.49% quarter-over-quarter to 57.58%, with James Simons being the largest institutional shareholder.

Lyell Immunopharma, Inc. Revenue Breakdown – NASDAQ:LYEL

Lyell Immunopharma, Inc. (NASDAQ: LYEL) generated $36.00K USD last year, primarily from its T-cell Therapies segment. This is a decrease from $61.00K USD reported in the previous year. The United States was the company's sole regional contributor to revenue.

LYEL|Lyell Immunopharma Inc|Price:12.615|Chg%:-0.165

Lyell Immunopharma Inc. (LYEL) has relatively healthy fundamentals and significant growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Despite this, the stock price is expected to trend down in the medium term, and technical indicators do not …

Lyell Immunopharma, Inc. SEC Filing (Jul 22, 2026)

This article reports on an SEC filing by Lyell Immunopharma, Inc. (NASDAQ: LYEL) dated July 22, 2026. The filing, designated as Form S-3 (Shelf Registration Statement), became effective on July 21, 2026, at 4:00 P.M. The filing impact and sentiment are noted as "Neutral."

Stifel initiates Lyell Immunopharma stock with buy, $44 target By Investing.com

Stifel has initiated coverage on Lyell Immunopharma Inc. (NASDAQ:LYEL) with a Buy rating and a $44 price target, despite the stock declining significantly in recent months. The firm highlights Lyell as a registrational-stage oncology company developing two cell therapy candidates for blood cancer and …

Innovative cellular therapeutics, Lyell director, sells $137 in stock

A director and 10% owner of Lyell Immunopharma, Innovative Cellular Therapeutics Holdings Ltd, recently sold 10 shares of LYEL stock for $137. This transaction occurred while LYEL shares traded at $12.92, down 46% over the last six months, and the company has a market …

Lyell Immunopharma (LYEL) insider entity sells 10 shares under plan

Innovative Cellular Therapeutics Holdings Ltd, a ten percent owner of Lyell Immunopharma, Inc. (LYEL), reported the sale of 10 shares of common stock at $13.70 per share on July 17, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, …

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of "Moderate Buy" by Brokerages

Insider Sell: Innovative Cellular Therapeutics Holdings Ltd Reduces Stake in Lyell Immunopharma Inc

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma Inc, sold 10 shares on July 16, 2026, reducing its total holdings to 2,857,490 shares. Lyell Immunopharma is a biotechnology company focused on cell therapies for solid tumors. The stock is considered significantly …

Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma common share disposal worth $137.3

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, sold 10 common shares on July 16, 2026, for $13.73 each, totaling $137.3. This transaction reduced their holdings to 2,857,490 common shares. The information originated from a filing with the U.S. Securities and …

Innovative Cellular trims Lyell Immunopharma (LYEL) stake with small share sale

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc. (LYEL), reported a sale of 10 shares of Lyell common stock on July 16, 2026, at $13.73 per share. This transaction was executed under a Rule 10b5-1 trading plan and reduced their …